Key result
Human challenge sera cross-react with major norovirus GII.4 variants, indicating conserved antigenic types.
Significant antigenic cross-reactivity exists among GII.4 norovirus variants from 1998 to 2012, highlighting conserved antigenic types that may impact vaccine development.
Supports consideration of cross-variant immunity in NoV vaccine development; leaves open whether this translates to clinical protection.
The GII.4 noroviruses (NoVs) are a single genotype that is responsible for over 50% of NoV gastroenteritis epidemics worldwide. However, GII.4 NoVs have been found to undergo antigenic drifts, likely selected by host herd immunity, which raises an issue for vaccine strategies against NoVs. We previously characterized GII.4 NoV antigenic variations and found significant levels of antigenic relatedness among different GII.4 variants. Further characterization of the genetic and antigenic relatedness of recent GII.4 variants (2008b and 2010 cluster) was performed in this study. The amino acid sequences of the receptor binding interfaces were highly conserved among all GII.4 variants from the past two decades. Using serum samples from patients enrolled in a GII.4 virus challenge study, significant cross-reactivity between major GII.4 variants from 1998 to 2012 was observed using enzyme-linked immunosorbent assays and HBGA receptor blocking assays. The overall abilities of GII.4 NoVs to bind to the A/B/H HBGAs were maintained while their binding affinities to individual ABH antigens varied. These results highlight the importance of human HBGAs in NoV evolution and how conserved antigenic types impact vaccine development against GII.4 variants.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2015) studied Norovirus GII.4 infection (n=6). Norovirus GII.4 variants was evaluated on Cross-reactivity and HBGA receptor blocking activity of sera against different GII.4 variants. Human challenge sera demonstrated significant cross-reactivity and HBGA receptor blocking activity against major norovirus GII.4 variants from 1998 to 2012, indicating conserved antigenic types.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: